跳至主要内容
临床试验/ACTRN12612000622808
ACTRN12612000622808进行中(未招募)3 期

A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naive HIV-infected Individuals Over 96 Weeks

Kirby Institute, Univeristy of New South Wales0 个研究点目标入组 124 人开始时间: 2012年6月8日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
124

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
16 Years 至 o limit(—)
性别
All

入选标准

  • All subjects entering into the main study protocol at participating centres will be eligible to enter this sub-study

排除标准

  • Existing neurological brain disease
  • Recent (<6months ) head injury
  • Current major depression or psychosis
  • Current alcohol abuse
  • Intended use of recreational drugs during study period
  • Uncontrolled medical conditions deemed to potentially interfere with cognitive function (e.g. uncontrolled diabetes, pyrexial illness, uraemia etc)

研究者

发起方
Kirby Institute, Univeristy of New South Wales

相似试验